OptiVERO Vero 細胞完整培養基套組 

疫苗製造商最完美選擇!

InVitria新推出OptiVERO，不需血清、不含任何血液衍生成分、不含動物衍生成分、不含植物水解物、化學成分確定的VERO細胞專用培養基。支持Vero細胞在T flask (2D culture) 與 microcarriers (3D culture) 的生長與擴增，並對於病毒生產進行了優化。

OptiVERO與市面上其他無血清VERO細胞培養基不同的地方在於，它甚至不含有未定義的二肽和三肽植物來源的水解產物，去除所有不確定的成分，將培養基中能引起的細胞擴增時的變異性降到最低，提高了疫苗研究和製造的一致性、準確性、安全性和可擴展性，從而加快生產時間。

研究成果於2018 World Vaccine Congress發表，此新型培養基表現出明顯優於市面上無血清培養基對VERO細胞的擴增能力和病毒生產，尤其是對於一些表達系統難以表達的病毒類型生產（如下圖）。

在流感病毒中，OptiVERO明顯表現出優於VP-SFM的生產能力，而登革熱和Zika病毒的產量與使用VP-SFM相當。

The OptiVERO media was subjected to productivity tests using a strain of Dengue and Zika flavivirus in WT VERO. For influenza, the genetically modified VERO subclone was utilized. WT VERO cells were grown for 3-4 days prior to infection. During the virus propagation phase, cultures were fed with a 45% glucose solution and the pH of the cultures were maintained at neutral using a 7.5% sodium bicarbonate solution. (A) FBS demonstrated a lag in the production of Dengue virus compared to VP-SFM and OptiVERO while (B) Zika virus did not demonstrate any significant differences between the media. Influenza virus demonstrated a higher degree of sensitivity to different media compared to the flavivirus Dengue and Zika. (C-D) VP-SFM failed to expand a strain of Influenza A and exhibited a significant delay in a second strain while OptiVERO was able to expand both of these virus strains very efficiently. (E-F) Influenza B strains 1 and 2 exhibited similar patterns in VP-SFM as this media induced a significant delay in the time to peak titer while OptiVERO was able to efficiently expand these virus types.

完整培養基套組包含基礎培養基、濃縮冷凍培養基和蛋白質補充劑。
經VERO細胞測試功能後出廠。

OptiVERO的優點包括：

• 降低細胞培養基的變異性
• 加速疫苗研究
• 提高疫苗製造的可擴展性和速度
• 降低製造時間和資源成本

現在可索取於2018 World Vaccine Congress發表的研究海報「Formulation of a blood-free and chemically defined virus production media for VERO cells」